The $600 Billion Blindspot: Why Menopause is the Next Big Bet in Longevity
It’s not just a life stage. It’s a biological shift that reshapes health, spending, and lifespan if you know where to look.
This newsletter is free. But it takes hours each week to research, write, and produce at this level. Here are 5 ways to support my work: 1. click “❤️” to amplify 2. subscribe 3. share this publication 4. buy me coffee 5. become a partner
Connect and collaborate with me here! Email | LinkedIn | Instagram
We have aging clocks down to the minute. But still no diagnostic tool for menopause.
We fund testosterone optimization. But not estrogen restoration. We engineer performance for aging male bodies. But ignore the most dramatic biological shift in aging female bodies.
This isn’t just a blind spot. It’s a mispriced market.
Because if you look closely at the demographic data, the clinical literature, and the capital flows, you’ll find something surprising:
Women experience a sharper biological decline during midlife. But the market is aging male.
New Here?
This is the last part of my five-part series on why longevity tech needs a gender lens. If you are an investor, operator, or women’s health advocate, start here.
→ Preorder the book: The Billion Dollar Blind Spot
→ Subscribe to the podcast: Blindspot Capital launched this week!
→ Join the Women’s Health Investing Masterclass & Choose your Tier: Core Access, Premium Access or Lite Access
Aging Is Not Gender-Neutral
Women live longer than men. But they spend more of those years in poor health1.
They are more likely to experience years lived with disability. More likely to be misdiagnosed. More likely to suffer from osteoporosis, autoimmune disease, Alzheimer’s, and postmenopausal cardiovascular events.
Yet most of the health metrics we use to define “healthy aging”; VO2 max, lean muscle mass, testosterone, glucose response, sleep efficiency are modelled on male physiology. Even wearables often ignore menstrual cycles, perimenopause shifts, or postmenopausal hormone baselines2.
So what happens when the investment thesis for longevity is built on male-coded data?
You miss the market hiding in plain sight.
Longevity Is the Macro Trend. But Menopause Is the Missed Signal.
There are over 1 billion women expected to be in menopause by 20303. Menopause is not a moment. It is a long arc of often 10–15 years of transition and symptoms that touch every system in the body.
Brain fog and cognitive change
Joint pain and musculoskeletal deterioration
Cardiovascular risk acceleration
Pelvic floor and sexual function changes
But here’s what’s rarely said: menopause is also predictable. It happens in midlife. It drives changes in behavior, clinical engagement, spending, and care-seeking. And it is the moment when millions of women start asking: What is happening to me?
That’s not just a medical question. It’s a market opportunity.
❤️ Enjoying this? If this post sparked something for you, click the ❤️ at the bottom. It helps more than you know and tells me you're reading.
Healthspan Is Where Women Lose Ground
Lifespan is increasing. But healthspan isn’t keeping up. Especially for women. After menopause, the biological deck reshuffles:
Women’s risk of heart disease rises sharply4
Bone density plummets, leading to fractures, frailty, and reduced mobility5
Alzheimer's disproportionately affects women, and early hormonal shifts may be a key driver6
Yet we still treat menopause as a lifestyle issue. Something to be managed with creams, supplements, or silence. And this is where the longevity industry is making its biggest mistake. Because if you want to extend healthspan, you have to intervene where decline begins. And for women, that is menopause.
The Alpha Is in the Reframe
Investors are chasing precision diagnostics, preventive medicine, and personalized care. But they are still using male baselines to define risk. What if they saw menopause for what it is?
A risk signal for neurodegeneration
A predictive marker for cardiometabolic decline
A biological gateway to new spending behavior, care engagement, and lifestyle change
That’s not niche. That’s alpha.
The next billion-dollar longevity company won’t just help men lift longer. It will help women live stronger. By recognizing that hormonal decline isn’t a side note. It’s the storyline.
One study estimates that while global longevity biotech investment topped USD 5.2 billion in 2022, less than 4% of that capital flowed into women’s health-focused innovation7.
If you care about changing the future of care, join me in the Women’s Health Investing Masterclass. Because awareness drives intention. And intention changes everything.
Estrogen Is Infrastructure
Hormones shape everything from brain chemistry to cardiovascular tone to immune resilience. Yet the biotech world has treated estrogen as a reproductive hormone not a systemic regulator.
This is changing. Slowly. Startups like Midi Health, Elektra Health, and Vira Health are beginning to fill the gap but they remain undercapitalized relative to their male-focused peers.
Researchers are mapping perimenopause to long-term disease trajectories. Clinics are being redesigned around midlife care. But the capital still lags. Because until we change the thesis, we won’t change the flow.
Rewiring the System
This five-part series has traced the capital chain:
And now: what we must build next
We need funding models that back the messy, nonlinear, multi-systemic reality of women’s aging. We need clinical trials that treat menopause as a measurable shift. We need longevity tech that centers the biology of the people who live longest.
And we need narrative power from platforms, from investors, from all of us. Because markets don’t move unless someone tells the story first.
If this essay moved you, share or restack it.
Public pressure and narrative power change incentives but only when we show up.
Those who can fund the future, should. But every one of us can amplify the future we want to see. Share this with your network. With your employer. With your doctor. With anyone who still thinks this is “just a women’s issue.”
Because the future of care depends on who speaks up and who gets heard.
This is the last part of a five-part series on why longevity needs a gender lens. To go deeper, pre-order my upcoming book The Billion Dollar Blind Spot to learn why women’s health is the future of healthcare investing.
Join Our Network
Are you building or backing credible, under-the-radar solutions in women’s health?
We want to hear from you. Reach out privately or reply to this post. FHV curates brands and breakthroughs that deserve broader attention in the women’s health ecosystem.
I write weekly at FemmeHealth Ventures Alliance about capital, care, and the future of overlooked markets. If you are building, backing, or allocating in this space, I’d love to connect.
Disclaimer & Disclosure
This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.
References
WHO Global Health Estimates, 2023
Nature Digital Medicine, "Gender Bias in Wearable Design" (2022)
UN Demographic Forecast, "Women in Menopause by 2030" (2021)
American Heart Association, "Menopause and Cardiovascular Risk" (2022)
Mayo Clinic, "Bone Density After Menopause" (2023)
Alzheimer’s Association, "Sex Differences in Alzheimer's Disease" (2022)
FemTech Analytics, "Longevity Industry in Women’s Health" (2023)
Even when menopause is finally noticed, it’s still framed as a market inefficiency. That’s the problem. Women’s health doesn’t need better venture decks. It needs people who can actually read what women’s bodies are saying.